School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Krystal Biotech, Inc. KRYS

Healthcare · Biotechnology

$331.61last close 2026-10-09 · market cap $9.82B · delayed data

Trailing returns

1M-4.73%
3M-10.68%
6M+28.37%
1Y+75.68%
5Y+542.66%

Basis: Adjusted daily closes.

What it does

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Open KRYS in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies